KQB198

Kumquat Biosciences Inc. · Phase 2 active Small molecule

At a glance

Generic name	KQB198
Sponsor	Kumquat Biosciences Inc.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Hematologic Malignancies (PHASE1)
KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting (PHASE2)
A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

KQB198 CI brief — competitive landscape report
KQB198 updates RSS · CI watch RSS
Kumquat Biosciences Inc. portfolio CI